Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA). J of Skin 2025, 9 (6), s664. https://doi.org/10.25251/h3w8px06.